Slide 1: 3Q 2024 Business Update
—_ ~ ocugen. > ee Courageous Innovation Dedicated to Bringing Transformative Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally 3Q 2024 Business Update November 8, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical
Slide 3: First-In-Class Modifier Gene Therapy Programs
ocugen. ~<a First-In-Class Modifier Gene Therapy: * OCU400 Phase 3 liMeliGhT Clinical Trial Retinitis pigmentosa * OCU410 Phase 2 ArMaDa Clinical Trial Geographic atrophy ¢ OCU410ST Phase 1/2 GARDian Clinical Trial Stargardt disease
Slide 4: OCU400 Modifier Gene Therapy — A Paradigm Shift in Gene Therapy
OCU400 Modifier Gene Therapy — A Paradigm Shift in Gene Therapy v Health Canadaapprovedinitiation of OCU400 Phase3 liMeliGhT trial for the treatment of retinitis pigmentosa (RP) v Received FDA approval of expanded access program (EAP) for adult patients with RP Upcoming anticipated catalysts: * Clin
Slide 5: OCU400: RP Market Opportunity
OCU400: RP Market Opportunity OCU400 is designed to address the shortcomings of current gene therapy approaches—a broad spectrum, gene-agnostic approach to genetically diverse inherited retinal diseases and potential one-time curative therapy witha single sub-retinal injection Retinitis Pigmentosa (
Slide 6: OCU410: A Single-Injection Approach to Address Unmet Need
OCU410:A Single-Injection Approach to Address Unmet Need Y Dosing is underway in the OCU410 Phase 2 ArMaDa clinical trial, following the completion of Phase 1 low, medium, and high dose cohorts, which involved nine patients with geographic atrophy (GA) Phase 2 trial is actively recruiting a larger p
Slide 7: OCU410 Program Overview—Phase 2
OCU410 Program Overview—Phase 2 Study Objective and Modality * Assess the safety and efficacy of OCU410 in subjects with GA secondary to dry age-related macular degeneration (dAMD) * Single, unilateral subretinal injection using a modifier gene therapy platform Overall Strategy Dose Expansion: * Exp
Slide 8: OCU410ST: Modifier Gene Therapy Addressing Shortcomings of Current Approaches
OCU410ST: Modifier Gene Therapy Addressing Shortcomings of Current Approaches v Dataand Safety Monitoring Board (DSMB) approved enrollment for the second phase of the OCU410ST Phase 1/2 clinical trial Upcoming anticipated catalyst: Preliminary safety and efficacy update from ongoing Phase 1/2 clinic
Slide 9: OCU200: Biologic Program for the Treatment of Diabetic Macular Edema
OCU200: Biologic Program for the Treatment of Diabetic Macular Edema v U.S.FDAcleared the IND for the Phase 1 clinical trial evaluating OCU200 for diabetic macular edema (DME) Upcoming anticipated catalyst: Initiate Phase 1 clinical trial in the fourth quarter of 2024 Approximately 30 to 40% of DME
Slide 10: Financial Update
Financial Update
Slide 11: Financial Update
Financial Update Three months ended September 30, Statement of Operations 2024 2023 Research and development expense $8.1 $7.0 General and administrative expense 6.3 S31 Other income (expense), net 0.3 0.7 Net loss $(13.0) $11.7) Balance Sheet bats September 2024 eae ed Cash and restricted cash $39.
Slide 12: Questions & Answers
Questions & Answers
Slide 13: Near-Term Targeted Milestones
Near-Term Targeted Milestones OCU400 Phase 3 dosing and recruitment updates — 1H2026 BLA/MAA filing targets on track New data update from OCU400 Phase 1/2 RP & LCA Preliminary safety/efficacy update - OCU410 Phase 1/2 clinical trial (GA) Preliminary safety/efficacy update - OCU410ST Phase 1/2 clinic
Slide 14: Ocugen Vision
Ocugen Vision We're here to make an impact. At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving science in new directions and breaking new ground. — ocugen. 4 —